This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Released: ·Last reviewed: ·Methodology v4.1
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.
GLP-1 microdosing
"Microdosing" GLP-1 medication is a popular but loosely defined idea. This hub distinguishes clinician-directed low-dose regimens from marketing, and lays out what the evidence supports.
Quick answer
GLP-1 "microdosing" refers to using doses below the standard label schedule, often for maintenance or to limit side effects. It is not an FDA-approved protocol and the supporting evidence is limited. Individualized low-dose regimens should be clinician-directed, not self-managed.
Where should you read next?
Microdose semaglutide
Low-dose semaglutide regimens
Microdose tirzepatide
Low-dose tirzepatide regimens
Microdose GLP-1 cost
Whether lower doses cost less
Microdose GLP-1 safety
What lower doses do and don't change
Best microdose programs
Providers offering low-dose plans
Sources
- U.S. Food and Drug Administration — approval and compounding status.
- Primary clinical literature cited on child pages.
- Our methodology and source standards.
How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.